# Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate

> **NCT00203047** · PHASE4 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 414 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Glatiramer Acetate
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00203047
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 414 (ACTUAL)
- **Why stopped:** Slow enrollment decreased sample size; No unexpected safety issues.
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203047, "Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00203047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*